The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Shifting from the single to the multitarget paradigm in drug discovery
Open accessAbstract
Increasing evidence that several drug compounds exert their effects through interactions with multiple targets is boosting the development of research fields that challenge the data reductionism approach. In this article, we review and discuss the concepts of drug repurposing, polypharmacology, chemogenomics, phenotypic screening and highthroughput in vivo testing of mixture-based libraries in an integrated manner. These research fields offer alternatives to the current paradigm of drug discovery, from a one target–one drug model to a multiple-target approach. Furthermore, the goals of lead identification are being expanded accordingly to identify not only ‘key’ compounds that fit with a single-target ‘lock’, but also ‘master key’ compounds that favorably interact with multiple targets (i.e. operate a set of desired locks to gain access to the expected clinical effects).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Einfluss der Configuration auf die Wirkung der Enzyme
Fischer, E. (1894) · Berichte der deutschen chemischen Gesellschaft · doi:10.1002/cber.18940270364 · Cited by 1,835
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Chen, C. Y.-C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015939 · Cited by 806
Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review
Cheng, T., Li, Q., Zhou, Z., Wang, Y., & Bryant, S. H. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9322-0 · Cited by 574
Recognizing Pitfalls in Virtual Screening: A Critical Review
Scior, T., Bender, A., Tresadern, G., Medina-Franco, J. L., Martínez-Mayorga, K., Langer, T., Cuanalo-Contreras, K., & Agrafiotis, D. K. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200528d · Cited by 438
Self-citationDrug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
Chemical space as a source for new drugs
Reymond, J.-L., van Deursen, R., Blum, L. C., & Ruddigkeit, L. (2010) · MedChemComm · doi:10.1039/c0md00020e · Cited by 347
Cited by
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Tsubaki, M., Tomii, K., & Sese, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty535 · Cited by 688
Network Pharmacology Approach for Medicinal Plants: Review and Assessment
Noor, F., Tahir ul Qamar, M., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022) · Pharmaceuticals · doi:10.3390/ph15050572 · Cited by 540
Salehi, B., Zakaria, Z. A., Gyawali, R., Ibrahim, S. A., Rajkovic, J., Shinwari, Z. K., Khan, T., Sharifi-Rad, J., Ozleyen, A., Turkdonmez, E., et al. (2019) · Molecules · doi:10.3390/molecules24071364 · Cited by 523
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 360
Drug repositioning and repurposing: terminology and definitions in literature
Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S., & Schutjens, M.-H. D. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.001 · Cited by 323
Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases
Makhoba, X. H., Viegas Jr., C., Mosa, R. A., Viegas, F. P., & Pooe, O. J. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 321
Multi-target approach for natural products in inflammation
Koeberle, A., & Werz, O. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.006 · Cited by 317
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
A review of large language models and autonomous agents in chemistry
Ramos, M. C., Collison, C. J., & White, A. D. (2025) · Chemical Science · doi:10.1039/d4sc03921a · Cited by 274
Pohl, F., & Kong Thoo Lin, P. (2018) · Molecules · doi:10.3390/molecules23123283 · Cited by 272
Active-learning strategies in computer-assisted drug discovery
Reker, D., & Schneider, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.004 · Cited by 261
Sulfonamide derivatives as multi-target agents for complex diseases
Apaydın, S., & Török, M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.041 · Cited by 256
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
“During the last decade, an increasing number of studies converged on proposing that many drugs, initially designed for a unique therapeutics target, are in fact expected to hit on average between 6 and 13 different targets (51, 52).”
BackgroundDeepCPI: A Deep Learning-Based Framework for Large-Scale in Silico Drug Screening
Wan, F., Zhu, Y., Hu, H., Dai, A., Cai, X., Chen, L., Gong, H., Xia, T., Yang, D., Wang, M.-W., et al. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.04.003 · Cited by 92
Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine
Johnson, K. W., Shameer, K., Glicksberg, B. S., Readhead, B., Sengupta, P. P., Björkegren, J. L. M., Kovacic, J. C., & Dudley, J. T. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.11.010 · Cited by 83
Xia, B., Gerstin, E., Schones, D. E., Huang, W., & Steven de Belle, J. (2016) · Aging · doi:10.18632/aging.101107 · Cited by 41
“In addition, one important trend for drug discovery is the ongoing shift from single-target-oriented molecules to network- or biological system-active compounds and to “epi-drugs” [67-69].”
BackgroundHow to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors
Pogodin, P. V., Lagunin, A. A., Rudik, A. V., Filimonov, D. A., Druzhilovskiy, D. S., Nicklaus, M. C., & Poroikov, V. V. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00133 · Cited by 40
Recent progress in the research of small molecule HIV-1 RNase H inhibitors
Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140120121158 · Cited by 34
Zhao, M., Yuan, M., Yang, Y., & Xu, S. X. (2023) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3225296 · Cited by 22
Issa, N. T., Kruger, J., Wathieu, H., Raja, R., Byers, S. W., & Dakshanamurthy, S. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1065-y · Cited by 22
Romero, J. C., Martínez-Vázquez, A., Herrera, M. P., Martinez-Mayorga, K., Parra-Delgado, H., Pérez-Flores, F. J., & Martínez-Vázquez, M. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.10.028 · Cited by 15
The functional therapeutic chemical classification system
Croset, S., Overington, J. P., & Rebholz-Schuhmann, D. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt628 · Cited by 11
A precise comparison of molecular target prediction methods
He, T., Caba, K., & Ballester, P. J. (2025) · Digital Discovery · doi:10.1039/d5dd00199d · Cited by 4
Metadata
- Authors
- Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 18
- Issue
- 9-10
- Pages
- 495-501
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1988452823
- Cited by
- 483
- References
- 53
- FWCI
- 48.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.